Safety And Immunogenicity Of A Polyvalent Escherichia Coli Vaccine In Human Volunteers
| Autor: | Emil Fürer, Andrew W. Artenstein, Jerald C. Sadoff, Alan S. Cross, J Stanley Cryz Jr, Terry Fredeking, John U. Que |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Lipopolysaccharides
Virulence Factors Recombinant Fusion Proteins Bacterial Toxins Escherichia coli Vaccines Exotoxins Enzyme-Linked Immunosorbent Assay medicine.disease_cause Neonatal meningitis Microbiology Escherichia coli medicine Humans Immunology and Allergy Escherichia coli Infections ADP Ribose Transferases biology Pseudomonas aeruginosa Polyvalent Vaccine business.industry Immunogenicity Polysaccharides Bacterial O Antigens medicine.disease Antibodies Bacterial Virology Infectious Diseases Antibody Formation Bacterial Vaccines Adjunctive treatment biology.protein Antibody business |
| Zdroj: | Journal of Infectious Diseases. 170:834-840 |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | Since a limited number of O serogroups account for nearly 70% of bacteremic and meningitic Escherichia coli isolates, a polyvalent vaccine was made by conjugating a Pseudomonas aeruginosa exotoxin A carrier protein to the O polysaccharide of 12 serogroups of E. coli (O1, O2, O4, O6-O8, O12, O15, O16, O18, O25, O75). No serious reactions occurred in 88 vaccinees. Four-fold or greater increases in ELISA antibody levels over baseline were greatest (> 60% of vaccinees) for O1, O2, O6-O8 and O15; intermediate (approximately 50%) for O18 and O75, and poorest (> or = 45%) for O4, O12, O16, and O25. Responses with functionally active opsonophagocytic antibody generally paralleled ELISA antibody responses. With the availability of a safe, immunogenic E. coli vaccine, active and passive immunization strategies merit further development as adjunctive treatment for E. coli bacteremia and neonatal meningitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|